Study of Topical Ocular PAN-90806 in PDR

Completed · Phase 1

Conditions studied: Diabetic Retinopathy

In brief

The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with proliferative diabetic retinopathy.

Key facts

Study ID

NCT02475109

Run by

PanOptica, Inc.

People needed

10

Starts

2015-08-01

Expected to finish

2016-07-01

Last updated by the study team

2016-09-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18 years or older with type 1 or type 2 diabetes
• Proliferative diabetic retinopathy (PDR) in study eye retina with or without diabetic macular edema (DME) involving the center of the macula
• Demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study eye

You may not qualify if…

• Current or recent use (within the last 3 months) of anti-vascular endothelial growth factors (anti-VEGF) in either eye;
• Uncontrolled hypertension despite use of antihypertensive medications
• Unwillingness to refrain from wearing contact lenses for the duration of the study.
• Participation in any investigational drug or device study, systemic or ocular, within past 3 months
• Women who are pregnant or nursing
• Known serious allergies or hypersensitivity to the fluorescein dye used in angiography or to the components of the PAN-90806 formulation

Where it is running

• Valley Retina Institute — Harlingen, Texas, United States
• Valley Retina Institute — McAllen, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.